Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma-Reference-Cited by-同舟云学术

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

Published:2011-01-21 Issue:5 Volume:66 Page:671-678
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:

Author:

Bousquet J.,Siergiejko Z.,Świebocka E.,Humbert M.,Rabe K. F.,Smith N.,Leo J.,Peckitt C.,Maykut R.,Peachey G.

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1398-9995.2010.02522.x/fullpdf

Reference13 articles.

1. European Medicines Agency (EMEA) Omalizumab (Xolair®) summary of product characteristics (EU) http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/emea-combined-h606en.pdf

2. Genentech Inc Omalizumab (Xolair ® ) full prescribing information (US), July 2007 http://www.gene.com/gene/products/information/immunological/xolair/insert.jsp

3. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma;Bousquet;Allergy,2005

4. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE;Humbert;Allergy,2005

5. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study;Niven;Respir Med,2008

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Direct comparative study of anti-IgE and anti-IL4Rα therapy effectiveness in patients with severe allergic and mixed bronchial asthma;Meditsinskiy sovet = Medical Council;2024-06-06

2. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials;European Respiratory Review;2024-04-24

3. Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study;Children;2024-01-28

4. Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis;Therapeutic Advances in Respiratory Disease;2024-01

5. A Randomized, Single‐Dose, Parallel‐Controlled Phase I Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers;Clinical Pharmacology in Drug Development;2023-12-06